ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 032,97
-0,18%
Dow Jones
41 911,71
0,00%
DAX
22 677,68
0,31%
Brent Oil
69,97
1,35%
Bitcoin
81 473,88
3,82%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Xeris Biopharma Holdings Inc (XERS)

  7. Xeris Biopharma Holdings Inc (XERS) Actualités

XERS

Xeris Biopharma (XERS)

Xeris Biopharma Holdings Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:XERS
DateHeureSourceTitreSymboleSociété
07/03/202522h11Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:XERSXeris Biopharma Holdings Inc
06/03/202522h07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:XERSXeris Biopharma Holdings Inc
06/03/202513h21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XERSXeris Biopharma Holdings Inc
27/02/202513h00Business WireXeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025NASDAQ:XERSXeris Biopharma Holdings Inc
24/02/202514h00Business WireXeris Appoints Anh Nguyen, MD, MBA as Chief Medical OfficerNASDAQ:XERSXeris Biopharma Holdings Inc
05/02/202514h00Business WireXeris to Participate in Upcoming Investor ConferencesNASDAQ:XERSXeris Biopharma Holdings Inc
04/02/202501h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XERSXeris Biopharma Holdings Inc
21/01/202515h00PR Newswire (US)The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and AwarenessNASDAQ:XERSXeris Biopharma Holdings Inc
10/01/202513h00Business WireXeris Expects to Exceed Full-Year 2024 Financial GuidanceNASDAQ:XERSXeris Biopharma Holdings Inc
06/01/202522h15Business WireXeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:XERSXeris Biopharma Holdings Inc
26/11/202413h00Business WireXeris to Participate in Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:XERSXeris Biopharma Holdings Inc
08/11/202422h02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XERSXeris Biopharma Holdings Inc
08/11/202413h00Business WireXeris Biopharma Reports Third Quarter 2024 Financial ResultsNASDAQ:XERSXeris Biopharma Holdings Inc
31/10/202413h00Business WireXeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024NASDAQ:XERSXeris Biopharma Holdings Inc
08/08/202422h27Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:XERSXeris Biopharma Holdings Inc
08/08/202413h00Business WireXeris Biopharma Reports Second Quarter 2024 Financial ResultsNASDAQ:XERSXeris Biopharma Holdings Inc
25/07/202413h00Business WireXeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024NASDAQ:XERSXeris Biopharma Holdings Inc
08/07/202413h00Business WireXeris Biopharma Announces CEO Succession PlanNASDAQ:XERSXeris Biopharma Holdings Inc
03/06/202413h00Business WireXeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024NASDAQ:XERSXeris Biopharma Holdings Inc
30/05/202413h30Business WireXeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)NASDAQ:XERSXeris Biopharma Holdings Inc
30/05/202413h00Business WireXeris to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:XERSXeris Biopharma Holdings Inc
09/05/202413h00Business WireXeris Biopharma Reports First Quarter 2024 Financial Results and Recent EventsNASDAQ:XERSXeris Biopharma Holdings Inc
06/05/202413h00Business WireXeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta BionicsNASDAQ:XERSXeris Biopharma Holdings Inc
02/05/202413h00Business WireXeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:XERSXeris Biopharma Holdings Inc
03/04/202422h05Business WireXeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:XERSXeris Biopharma Holdings Inc
02/04/202413h00Business WireXeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:XERSXeris Biopharma Holdings Inc
06/03/202413h02Business WireXeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent EventsNASDAQ:XERSXeris Biopharma Holdings Inc
06/03/202413h00Business WireXeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin CapitalNASDAQ:XERSXeris Biopharma Holdings Inc
28/02/202413h00Business WireXeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024NASDAQ:XERSXeris Biopharma Holdings Inc
05/02/202413h00Business WireXeris to Present at the Oppenheimer 34th Annual Healthcare Life Science ConferenceNASDAQ:XERSXeris Biopharma Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:XERS

Dernières Valeurs Consultées

LSE
61ST
Anz Bank 44
TSXV
INEO
INEO Tech
USOTC
SSTRF
Silverstar (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces